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INTRODUCTION
Photodynamic therapy (PDT) is based on the relatively
specific accumulation of photosensitizers, such as
porphyrins, in dysplastic or malignant cells. After
intravenous, oral, or topical applications, the
photosensitizer drug predominantly concentrates in
tumor tissue and remains inactive until exposed to a
specific wavelength of light. When light is delivered to the
target cancer site, the photodynamic reaction induces
photochemical destruction of tumor tissue mediated by
singlet molecular oxygen and other reactive species
generated by the reaction of the activated photosensitizer
and mucosal oxygen. Damage to tissue occurs by several
pathways including cell necrosis, apoptosis, and ischemia
with vascular shutdown. The importance of inflammatory
and immune responses has been recognized [1]. Modern
PDT varies in the type of photosensitizer, the wavelength
and intensity of light used to activate the drug, and the
type of light distribution system used to apply the light [2].
Following health agency approvals throughout the world
for various cancers and other diseases, PDT is gradually
being accepted as a standard modality to be added to the
medical practioner's armamentarium [3].
Cholangiocarcinoma (CC) is the primary cancer of bile
ducts. Complete resection with negative margins is the
only treatment with a potential for cure, and 5-year
survival rates are 20 to 40% [4,5]. However, patients
usually present at an advanced stage, with more than 50%
of cases being unresectable at the time of diagnosis.
Recently, two randomized controlled trials have shown a
significant survival benefit in patients with unresectable
CC treated with PDT [6,7]. One of these studies also
showed a significant improvement in quality of life after
PDT and stenting [7]. 
Rationale for PDT as a local tumor ablation in hilar CC
CC is characterized by a slow growth rate and a low
propensity for metastasis. However, because of late
symptoms, a close proximity to important vascular
structures in the hilum of the liver, and a tendency to grow
into perineural tissue, CCs are seldom curative at the time
of diagnosis [8]. 
Even with an aggressive surgical approach, only 33% to
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The prognosis for hilar cholangiocarcinoma is limited by tumor spread along the biliary tree leading to
refractory obstructive cholestasis, cholangitis, and liver failure. Palliation with biliary endoprostheses results in
median survival times of 4-6 months for advanced bile duct cancer. Photodynamic therapy (PDT) is a local
photochemical tumor treatment consisting of a photosensitizing agent combined with laser irradiation of a distinct
wavelength. Tumor ablation with PDT combined with biliary stenting reduces cholestasis and significantly
improves median survival time. However, the treatment is not widely available, and the photosensitizers used for
PDT cause prolonged photosensitivity. Optimum control of tumor spread along the bile ducts and control of
cholestasis and cholangitis will prolong survival in one to two thirds of patients, and renders them suitable for
other antitumor therapies. (Korean J Intern Med 2010;25:345-352)
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REVIEW50% of CCs are resectable, and negative histological
margins are obtained in only 28% [9]. A significant
survival advantage occurs for patients with negative
margins. The median survival time in a recent study by
Burke et al. [9] was 40 months overall in all resected
patients, 22 months in those with positive margins, and
greater than 60 months in those with negative margins. 
Usually the only therapeutic strategy for nonresectable
CCs is to improve cholestasis by endoscopic or
percutaneous drainage or biliary bypass. Although these
procedures do not influence tumor growth, and it is
unclear if they increase survival, they significantly
improve mental outlook and ameliorate symptoms such
as fatigue, diarrhea, anorexia, pruritus, jaundice, and poor
sleep patterns [10]. However, these procedures carry
some risk for procedure-related morbidity and mortality.
Early morbidity and 30-day mortality are significantly
higher following surgical procedures, whereas long-term
complications occur more frequently with endoscopic
therapy [11]. Interventional techniques are preferred,
because long-term complications are of minor
importance, with reported poor median survival times of
147 and 182 days, respectively [11]. 
Cholestasis can be relieved quickly in the majority of
patients with tumor stenoses in the distal and middle part
of the bile duct. Palliative intervention is limited in
proximal bile duct cancers. Independent of the type of
stricture, technically successful endoprosthesis placement
is possible in 84 to 96% of these patients [12,13]. However,
successful drainage (bilirubin decrease > 30% to 50%) is
only achieved in 69% to 91% of Bismuth type I and II
stenoses and in 15% to 73% of Bismuth type III and IV
tumors, which is reflected in the survival time of these
patients: 149 to 160 days for Bismuth type I, 84 to 131
days for Bismuth type II, and 62 to 70 days for Bismuth
type III strictures [12,14]. 
Although inserting a metal stent improves occlusion
rates and reduces the number of therapeutic
interventions, median survival time is not ameliorated
[15]. Attempts to affect tumor growth have been made
with radiotherapy or chemotherapy. Until now, however,
no randomized prospective studies concerning the effect
of these already long-used additional therapies are yet
available. The only retrospective comparative palliative
radiation therapy study showed no improvement in
median survival time (300 vs. 210 days) between
endoscopic biliary stenting alone and additional external-
beam radiotherapy and internal 
192Ir brachytherapy [16]. A
survival advantage in the radiotherapy group was
observed in the first 9 months. The median hospital stay
was 50 days with radiotherapy versus only 7 days with
endoprosthesis alone. 
Developing a treatment modality for local ablation of
the primary tumor could improve the outcome of curative
as well as palliative therapies. An 
192Ir dose of 35 Gy in a 1-
cm distance did not prolong median survival time (4.3 to 5
months) [17], but when combined with external beam
radiotherapy (30 Gy), palliative brachytherapy resulted in
median survival times of 10 to 10.5 months [15]. Another
modality for local tumor ablation of CC is PDT. 
Biological mechanism of PDT
PDT is a two-step procedure. A photosensitizing drug
known to preferentially accumulate in tumor cells is
administered, and the tumor is exposed to nonthermal
laser light of the appropriate photoactivating wavelength
after a time interval required for the drug to accumulate in
tumor tissue. A variety of candidate photosensitizing
agents are available for use in PDT, which are based upon
modifications of porphyrin, chlorine, and chlorophyll.
Phorphyrin-based photosensitizers, such as hematopor-
phyrin derivatives and its partly purified commercial
preparation, porfimer sodium (Photofrin II, Axcan,
Montreal, QC, Canada), are the most commonly used sen-
sitizers. Photofrin accumulates in CC cells with a tumor to
a normal tissue fluorescence ratio of 2:1, 24 and 48 hours
after administration [18]. Photofrin preferentially accu-
mulates in CC cells, reaching peak values during the first 2
days. This leads to a photochemical reaction, particularly a
type II reaction, and generates cytotoxic singlet oxygen or
other oxygen-derived free radicals [19]. These toxic prod-
ucts interact with a number of cellular components such
as microsomes, mitochondria, nuclei, and cell mem-
branes. The initial trigger is not yet known. The selective
sensitivity of the tumor microvasculature to PDT also
seems to play an important role [20]. 
The only relevant side-effect of PDT is phototoxicity.
For the most often used hematoporphyrin derivative,
phototoxicity lasts for 4 to 6 weeks after drug administr-
ation [21].
Technical aspects of PDT for cholangiocarcinoma
A translucent endoscopic retrograde cholangiography
cannula (triple lumen for guidewire, diffuser, and contrast
injection) is inserted into the tumor stenosis through
which a 400-µm thin quartz fiber with a cylindrical light
346 The Korean Journal of Internal Medicine Vol. 25, No. 4, December 2010diffuser and radiopaque markers at the tip (Optiguide
DCYL 200 series, QLT Phototherapeutics Inc., Vancouver,
Canada) is placed under fluoroscopic guidance across the
tumor stenosis. An alternative technique uses a preloaded
catheter [22]. After positioning a 0.035-inch guidewire
proximal to the biliary stricture, the preloaded catheter is
advanced over the guidewire using the monorail
technique and positioned into the stricture. The guidewire
is then withdrawn, and the diffuser tip with its radiopaque
markers is positioned across the stricture. However, the
peroral transpapillary approach has some limitations with
regard to appropriate application and patient follow-up.
Although flexible tip diffusing fibers are usually employed,
they may be rendered ineffective as a result of partial or
complete fracture of the laser diffuser tip caused by
bending during cannulation via the peroral route. In
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Figure 1. Percutaneous cholangiographic and choledochoscopic images of an advanced bile duct adenocarcinoma before and 4
months after the first photodynamic therapy (PDT) session. (A) Percutaneous cholangioscopy shows complete luminal obstruction of
the common hepatic duct as seen on percutaneous cholangioscopy. (B) Complete recannalization of the common hepatic duct is seen
on percutaneous cholangioscopy 4 months after PDT. (C) Complete luminal obstruction is seen at the bifurcation on cholangioscopy
before PDT. (D) A recannalized bile duct can be seen on cholangioscopy 4 months after PDT.
A B
C Dcomparison, percutaneous cholangioscopy-guided PDT
can provide an effective, homogeneous irradiation of the
targeted lesion with direct visual control (Fig. 1). This
procedure is easily performed and can be monitored
repeatedly without periodic peroral endoscopy, having
similar merits to the brief application and relatively less
pain associated with the routine exchange of stents in
percutaneous transhepatic biliary drainage treatment
[23]. The PDT site is usually temporarily obstructed due to
swelling and coagulation necrotic changes within 1 week
after PDT; therefore, it is necessary to insert an
exchangeable plastic endoprostheses or external drainage
tube. 
Photodynamic effect on cholangiocarcinoma
Wong et al. [24] showed up to a 60% reduction in
tumor volume after PDT with hematoporphyrin and
chlorine in nude mice inoculated with a human CC cell
line. The first hint of an in vivo beneficial effect for PDT
came from a single case report of McCaughan et al. [25].
CC cell lines show favorable cellular uptake kinetics for
sodium porfimer and excellent phototoxic cell damage in
response to PDT in vitro and in vivo in a human CC
xenograft model in nude mice [26]. The PDT effect was
evaluated after inoculating Buffalo female rats with rat
hepatoma cells. The mean complete necrosis size for a
single PDT session was 10.2 mm
3 [27]. Neoadjuvant PDT
for CC revealed that the tumoricidal depth of PDT using
porfimer is limited to 4- to 4.5-mm of tissue penetration
[28], which cannot eradicate a primary tumor when
invasion extends to a depth of 7 to 9 mm. Newer
photosensitizers lead to deeper tumor necrosis and a
shorter photosensitivity period. Meso-tetrahydroxyphenyl
chlorine has absorption in the near-infrared spectrum
(652 nm) and has the above characteristics. 
PDT outcomes for advanced hilar cholangiocarcinoma
In numerous uncontrolled studies, the combination of
PDT and biliary drainage has shown promising results in
patients with unresectable hilar CC (Table 1). 
In a pilot study, Ortner et al. [21] performed PDT in
patients with nonresectable CC Bismuth types III and IV
who, having failed endoprostheses placement, had the
poorest prognosis. Intraluminal photoactivation was
performed cholangioscopically 2 days after the
intravenous application of a hematoporphyrin derivative
(Photofrin II). Red light at 630 nm was emitted by an
argon-dye laser, and laser fibers with a core diameter of
400 mm with flexible cylindrical diffuser tips of 2.5 and
four lengths were used. The light flux was 310 and 190
mW/cm
2 with an 800 mW output, and the resulting dose
was 180 J/cm
2 by changing the irradiation time. Serum
bilirubin levels declined from 318 ± 72 µmol/L 103 ± 35
mmol/L (p = 0.0039) with no significant increase during
the two monthly follow-ups. Quality of life indices
improved dramatically (Karnofsky index 32.3 ± 8.13% to
68.9 ± 6.1%, p = 0.0078; World Health Organization
index 3.2 ± 0.36 to 1.7 ± 0.4, p = 0.016; performance
rating scale 13.6 ± 1.6 to 5 ± 0.93, p = 0.0078) and
remained stable during follow-up. Thirty-day mortality
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Table 1. Outcomes of photodynamic therapy for hilar bile duct cancer
Patients Type of study Bismuth type Median survival  Mean bilirubin 
(II ; III ; IV) time (mon, range) change (mg/dL)
Ortner (1998) [21] 9 Prospective 0 ; 0 ; 9 14.4 (3.0 - 18.9) 18.6 → 6.0
Berr (2000) [29] 23 Prospective 0 ; 2 ; 21 11.1 (0.8 - 50.7) 9.8 → 2.0
Rumalla (2001) [22] 6 Prospective 1 ; 3 ; 2 > 9 2.5 → 1.4
Ortner (2003) [7]
PDT 20 Randomized  0 ; 4 ; 16 16.3 (9.1 - 23.3) 10.7 → 1.6
Control 19 Prospective 2 ; 2 ; 15 3.2 (2.8 - 3.5) 10.1 → 10.5
Cheon (2004) [31] 27 Retrospective 1 ; 11 ; 13 18.6 12.5 → 2.6 
Wiedmann (2004) [30] 23 Prospective 0 ; 2 ; 21 11.2
Shim (2005) [23] 24 Prospective 0 ; 14 ; 10 14.1 (1.8 - 19.6) 14.0 → 2.7Cheon YK. PDT for cholangiocarcinoma 349
was 0%, 1-year survival was 77.7%, and median survival
time was 439 days. A recent prospective, open-label,
randomized, multicenter study with a group sequential
design compared PDT plus stenting (group A) with
stenting alone (group B) in patients with nonresectable CC
[7]. PDT resulted in survival prolongation (group A: n =
20; median, 493 days; group B: n = 19; median, 98 days; p
< 0.0001). PDT also improved biliary drainage and
quality of life. The authors concluded that PDT, given in
addition to best supportive care, improves survival in
patients with nonresectable CC. The study was terminated
prematurely, because PDT was so superior to simple
Figure 2. Photodynamic therapy (PDT) for a postoperative recurrent tumor. A 76-year-old man was referred to our hospital with
jaundice. He had undergone Whipple's operation due to a hilar cholangiocarcinoma 1 year ago. (A) Magnetic resonance imaging shows
a contrast enhanced hilar mass with an obstructing anastomosis site. (B) A choledochoscopy shows mucosal nodularity and
neovascularization at the anastomosis site. Biopsy specimens revealed adenocarcinoma. (C) Two days after PDT, a choledochoscopy
shows circumferential coagulation necrosis at the PDT-treated lesion. (D) A recannalized anastomotic site and small papillary changes
with no abnormal vessels can be seen on cholangioscopy 1 year after PDT. Choledochoscopic biopsy specimens revealed chronic
nonspecific inflammation.
A B
C Dstenting that further randomization was deemed
unethical. Similar results were obtained by another study
[31]. Twenty patients were treated with endoscopic biliary
drainage alone (group A), and 27 patients were treated
with PDT under percutaneous cholangioscopy with
additional percutaneous biliary drainage (group B) and
were analyzed retrospectively. The mean bilirubin level
declined effectively in both groups after treatment. One-
year survival was 28% in group A and 52% in group B (p<
0.05). Median survival time was 288 days in group A and
558 days in group B (p= 0.0143). 
PDT for recurrent tumors after resection or as a
neoadjuvant treatment
We experienced a case in which the survival time was
remarkably extended after applying PDT to a postoper-
ative recurrent tumor (Fig. 2). A small (n = 8) uncontrolled
study showed marked destruction of recurrent tumors, and
75% of patients were disease free after 2 years [32].
Neoadjuvant PDT was evaluated in seven patients with
advanced Bismuth type III and IV carcinoma, which was
thought to be unresectable after staging [28]. A curative
resection was performed after PDT in all patients; 83%
were recurrence free after 1 year, and 5-year survival was
71%. No relevant PDT side effects occurred except for a
minor intraoperative phototoxicity in one patient.
Assessment of response to PDT
Evaluating the therapeutic effects of PDT in patients
with CC presents a number of challenges. Ortner et al. [21]
evaluated the therapeutic effect of PDT in cases of
advanced bile duct cancer by comparing the tumor length
before and after PDT using the “mother-baby”
cholangioscopic technique; however, it has been argued
that their assessment was not objective. Although the
authors [7] reported reduced serum bilirubin levels after
PDT, plastic biliary endoprostheses were inserted in all
patients following the PDT procedure, making it difficult
to assess the direct effect of PDT for reducing serum
bilirubin. However, the PDT group might have benefited,
largely, from the number of endoscopic retrograde
cholangiopancreatography sessions. For this reason, we
do not consider serum bilirubin level to be an objective
parameter for assessing a PDT response. Ductal CCs
characteristically spread along or within the intrahepatic
bile ducts, making it difficult to define the response to
PDT based on changes in the tumor mass by computed
tomography (CT). Similarly, it may be difficult to obtain
objective results when the response to PDT is evaluated
based solely on the extent of reopening of an occluded bile
duct segment, as has been done in some studies [29]. We
assess the thickness of a tumor mass before and after PDT
treatment, measuring the thickest part of the tumor before
the treatment and every month thereafter [23]. The mean
thickness of the bile duct masses, as measured by
intraductal ultrasonography, decreased from 8.7 ± 3.7
mm before PDT to 7.1 ± 2.0 mm at 1 month (p= 0.176), to
7.1 ± 2.4 mm (p = 0.157) at 2 months, and declined
significantly to 5.8 ± 2.0 mm (p = 0.046) 3 months after
PDT. 
Some investigators have found that serum interleukin
(IL)-6 levels correlate with tumor burden in murine
cancer models [33,34], although this remains to be
demonstrated clinically. Goydos et al. [34] reported that
serum IL-6 levels are correlated with tumor burden as
measured by CT in patients with CC; 2 weeks after tumor
resection in three of 15 patients, IL-6 levels had dropped
to undetectable levels in two patients and dropped by
almost 10-fold in a third patient. Our results demonstrated,
similarly, that IL-6 was significantly reduced (38.2 ± 9.9
pg/mL; p = 0.008) 1 month after PDT, as compared with
the pretreatment level (282.1 ± 121.8 pg/mL); tumor
thickness also decreased following PDT. In contrast, IL-6
levels did not change 1 month after endoscopic retrograde
biliary drainage [35].
CONCLUSION
Patients with unresectable CC have a very short life
expectancy. PDT is the first palliative treatment option
that has shown efficacy in two randomized prospective
studies. PDT improves survival, jaundice, quality of life, is
well tolerated, and can be repeated without losing efficacy.
PDT seems to be a promising therapeutic approach for
nonresectable CC. PDT combines treating cholestasis with
reducing tumor growth; therefore, it should be considered
as standard care for palliation of CC. If results are
confirmed, new photosensitizers with greater penetration
depth and shorter photosensitivity should be used, or
better drug targeting or combination therapies should be
implemented to induce additional tumor necrosis. As PDT
treatment is not available in all centers, patients should be
referred to a specialized center that conducts PDT. It is
still unknown whether radiotherapy and/or chemotherapy
further improve the fate of PDT patients. It is now
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necessary to confirm these data in an extended
randomized multicenter study, as PDT for recurrent
tumors after surgery and neoadjuvant PDT remains
experimental. 
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